These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26152414)

  • 21. Evaluation of heat-treating heartworm-positive canine serum samples during treatment with Advantage Multi
    Savadelis MD; Roveto JL; Ohmes CM; Hostetler JA; Settje TL; Dzimianski MT; Moorhead AR
    Parasit Vectors; 2018 Feb; 11(1):98. PubMed ID: 29458396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential efficacy of monthly administrations of spot-on moxidectin 2.5%/imidacloprid 10% in the simultaneous prevention of major canine filarioses.
    Traversa D; Mazzi A; Di Cesare A; Famigli Bergamini P; Fracassi F; Fanini G; Aste G; Pampurini F; Boari A
    Parasitol Res; 2013 Nov; 112(11):3753-6. PubMed ID: 23925446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of the safety and efficacy of 10% imidacloprid + 2.5% moxidectin topical solution for the treatment of ear mite (Otodectes cynotis) infestations in dogs.
    Arther RG; Davis WL; Jacobsen JA; Lewis VA; Settje TL
    Vet Parasitol; 2015 May; 210(1-2):64-8. PubMed ID: 25801226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection of dogs against canine heartworm infection 28 days after four monthly treatments with Advantage Multi® for Dogs.
    Bowman DD; Grazette AR; Basel C; Wang Y; Hostetler JA
    Parasit Vectors; 2016 Jan; 9():12. PubMed ID: 26746229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental infection with Ancylostoma ceylanicum in dogs and efficacy of a spot on combination containing imidacloprid 10% and moxidectin 2.5% (Advocate/Advantage Multi, Bayer Animal Health).
    Taweethavonsawat P; Chungpivat S; Satranarakun P; Traub RJ; Schaper R
    Parasitol Res; 2010 May; 106(6):1499-502. PubMed ID: 20349196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study.
    Segev G; Rojas A; Lavy E; Yaffe M; Aroch I; Baneth G
    Parasit Vectors; 2018 Mar; 11(1):127. PubMed ID: 29506575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the efficacy of ProHeart
    Bowman DD; McTier TL; Adams EL; Mahabir SP; Login JA; Bidgood T; Woods DJ
    Parasit Vectors; 2017 Nov; 10(Suppl 2):502. PubMed ID: 29143654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of orally administered fluralaner (Bravecto™) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs.
    Fourie JJ; Liebenberg JE; Horak IG; Taenzler J; Heckeroth AR; Frénais R
    Parasit Vectors; 2015 Mar; 8():187. PubMed ID: 25881320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heat pretreatment of canine samples to evaluate efficacy of imidacloprid + moxidectin and doxycycline in heartworm treatment.
    Bendas AJR; Mendes-de-Almeida F; Von Simson C; Labarthe N
    Parasit Vectors; 2017 May; 10(1):246. PubMed ID: 28526068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a single topical application of Advantage Multi (= Advocate) Topical Solution (10% imidocloprid + 2.5% moxidectin) in the treatment of dogs experimentally infected with Crenosoma vulpis.
    Conboy G; Hare J; Charles S; Settje T; Heine J
    Parasitol Res; 2009 Aug; 105 Suppl 1():S49-54. PubMed ID: 19575225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical Compatibility and Safety of Imidacloprid/Flumethrin Collar (Seresto®) Concomitantly Used with Imidacloprid/Moxidectin (Advocate®, Advantage® Multi) and Emodepside/Praziquantel (Profender®) Spot-on Formulations.
    Krüdewagen EM; Remer C; Deuster K; Schunack B; Wolken S; Crafford D; Fourie J; Stanneck D
    Parasitol Res; 2015 Aug; 114 Suppl 1():S55-80. PubMed ID: 26152409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed canine heartworm (Dirofilaria immitis) microfilarial reduction following Advocate™ for dogs (imidacloprid, moxidectin) treatment.
    Power RI; Šlapeta J
    Vet J; 2024 Oct; 307():106209. PubMed ID: 39098470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of canine generalized demodicosis associated with hyperadrenocorticism with spot-on moxidectin and imidacloprid.
    Huang HP; Lien YH
    Acta Vet Scand; 2013 May; 55(1):40. PubMed ID: 23663380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a spot on combination containing imidacloprid 10% and moxidectin 1% (Advocate(®)/Advantage(®) Multi, Bayer Animal Health) against Ancylostoma ceylanicum in cats.
    Taweethavonsawat P; Chungpivat S; Watanapongchati S; Traub RJ; Schaper R
    Vet Parasitol; 2012 Nov; 190(1-2):289-93. PubMed ID: 22677133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoprophylaxis of Dirofilaria immitis (Leidy 1856) infection at a high challenge environment.
    Labarthe NV; Willi LM; Paiva JP; Miranda MG; Zoreck K; Almeida FM
    Parasit Vectors; 2015 Oct; 8():523. PubMed ID: 26459036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study.
    Heine J; Krieger K; Dumont P; Hellmann K
    Parasitol Res; 2005 Oct; 97 Suppl 1():S89-S96. PubMed ID: 16228281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-Arsenical heartworm adulticidal therapy using topical moxidectin-imidacloprid and doxycycline: A prospective case series.
    Ames MK; VanVranken P; Evans C; Atkins CE
    Vet Parasitol; 2020 Jun; 282():109099. PubMed ID: 32450463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Persistent Preventive Efficacy of 2.5 % Moxidectin/10 % Imidacloprid Spot-on (Advocate®, Advantage® Multi) in Dogs Experimentally Infected with Angiostrongylus vasorum.
    Böhm C; Petry G; Schmidt H; Raue K; Barthel F; Schaper R
    Parasitol Res; 2017 Aug; 116(Suppl 1):1-10. PubMed ID: 28717944
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of imidacloprid/moxidectin spot-on solution and fenbendazole in the treatment of dogs naturally infected with Angiostrongylus vasorum (Baillet, 1866).
    Willesen JL; Kristensen AT; Jensen AL; Heine J; Koch J
    Vet Parasitol; 2007 Jul; 147(3-4):258-64. PubMed ID: 17544583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventive efficacy of four or six monthly oral doses of 24 µg/kg moxidectin compared to six monthly doses of Heartgard® Plus or Interceptor® Plus against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs.
    Kryda K; Holzmer S; Everett WR; McCall JW; Mahabir SP; McTier TL; Maeder SJ
    Parasit Vectors; 2020 Jul; 13(1):339. PubMed ID: 32660542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.